Company Profile
PTC Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- PTCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
70.85 USD (+2.37%)
Close
Last updated: August 6, 2026
5.66B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PTCT closed up 2.37% at $70.85. No new same-company headline was identified in the current news window.
Company overview
Rare-Disease Medicines
PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases.
Commercial Portfolio
Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise. PTC also markets additional rare-disease products in multiple regions.
Vatiquinone
Vatiquinone is an oral small molecule being advanced through a registration study for a rare neurologic disorder following regulatory feedback.
Votoplam
Votoplam is an oral small-molecule splicing modifier under long-term evaluation in Huntington's disease through a collaboration with Novartis.
Future catalysts
Initiation of an open-label registration study of vatiquinone in the third quarter of 2026.
Recent news
- 01
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Source: PTC Therapeutics, Inc.
- 02
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Source: PTC Therapeutics, Inc.
- 03
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: PTC Therapeutics, Inc.
- 04
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
Source: PTC Therapeutics, Inc.
- 05
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
Source: PTC Therapeutics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PTC Therapeutics, Inc. (PTCT)?
PTC Therapeutics, Inc. (PTCT) most recently closed at 70.85 USD, a +2.37% move versus the previous session.
What is the market cap of PTC Therapeutics, Inc. (PTCT)?
PTC Therapeutics, Inc. currently has a market capitalization of 5.66B USD on BioPharmSignal.
What does PTC Therapeutics, Inc. do?
Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise. PTC also markets...
On which exchange is PTCT stock listed?
PTC Therapeutics, Inc. (PTCT) is associated with NASDAQ, United States, Biopharma.
What is Rare-Disease?
Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders.
Which conditions is PTC Therapeutics, Inc. targeting with Rare-Disease?
PTC Therapeutics, Inc. is associated with metabolic disease based on its company overview and current catalyst commentary.
How does PTC Therapeutics, Inc. describe recent progress with Rare-Disease?
Initiation of an open-label registration study of vatiquinone in the third quarter of 2026.
What is Medicines?
Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders.